Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
Objective
Primary Objectives: To compare overall survival (OS) between patients receiving SAbR + systemic therapy (SABR+ST) versus systemic therapy (ST) only. To compare average AE score between SAbR+ST arm and ST only arm.
Secondary Objectives: To compare global health status / quality of life (QOL) between patients receiving SAbR+ST versus ST only. To compare progression-free survival (PFS) between the arms.
